The above are suggestions for use of compounded tirzepatide while the FDA approved therapies remain on shortage
The most common side effects are gastrointestinal, including nausea (15-46% of patients), diarrhea (12-22%), decreased appetite (up to 27%), constipation (7-17%), and vomiting (2-10%), with rates varying by dose and indication
Adverse effects of GLP-1 receptor agonists
Your provider will confirm eligibility, guide dosing, monitor side effects, and adjust your plan as needed over time
Conclusion Metformin and Tirzepatide form a potent combination in the management of type 2 diabetes, utilizing their distinct mechanisms to enhance glycemic control and promote body mass reduction